Although progression-free survival was similar across racial groups, overall survival was shorter for Black patients with ...

Success is no longer just about prolonging survival, but about enabling patients to live well after cancer, with fewer long-term toxicities and greater quality of life. This shift reflects both ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Study finds similar PFS across races in ovarian cancer trials, but Black patients had shorter OS, raising concerns about disparities after trial completion.

Cancer treatment focuses on removing disease from the body. Survivorship focuses on reducing avoidable risk where possible. We cannot control every exposure. Modern life includes synthetic materials, ...

For many patients with cancer, it is never too soon to begin discussing fertility preservation options as they begin their cancer journeys. For many patients with cancer, it is never too soon to begin ...

Early findings from the ongoing MIRACLE clinical trial suggest that the investigational drug annamycin, given with cytarabine, may help more patients with relapsed or refractory acute myeloid leukemia ...

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

Dr. Ashkan Emadi, principal investigator of a first-in-world phase 2 clinical trial evaluating subcutaneous Blincyto ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

A new study led by Mass General Brigham suggests that a more proactive, tech-driven approach to palliative care can ...

The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...